Effect of Acute Phenylcapsaicin Intake on Trained Cross-Training Athletes

NCT06784271 | Active Not Recruiting

• 1 other identifier: CROSSCAPS
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate the effect of acute phenylcapsaicin intake during a cross-training session on perceived exertion, performance, and recovery in cross-training athletes.

Conditions

Performance

Keywords

Phenylcapsaicin; performance; concurrent exercise; nutrition; recovery

Outcome Measures

Primary Outcomes (2)

• Performance

  Performance measured through the countermovement jump

  60min

• Performance

  Deep squat test at 70% of repetition maximum

  60min

Secondary Outcomes (7)

• Heart rate

  60min

• Subjective fatigue throughe the RPE scale

  60min

• Recovery

  60min

• Delayed-onset muscle soreness (DOMS)

  60min

• Capillar lactate levels

  60min

Study Arms (2)

Phenylcapsaicin

EXPERIMENTAL

2.5 mg of Phenylcapsaicin

Dietary Supplement: Phenylcapsaicin

Placebo

PLACEBO COMPARATOR

Preparation of colorants, sweeteners, aromas, and acidulants

Dietary Supplement: Placebo

Interventions

Phenylcapsaicin DIETARY_SUPPLEMENT

2.5mg of Phenylcapsaicin

Phenylcapsaicin

Placebo DIETARY_SUPPLEMENT

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age: 18-35 years.
• Body mass index: 18.5-30 kg/m2.
• Ability to understand the instructions, objectives, and study protocol.
• Minimum of 3 years of experience in crosstraining, with at least 6 hours of weekly training over the past 3 months.
• Resident on the island of Tenerife.

You may not qualify if:

• History of a significant adverse cardiovascular event, renal insufficiency, cirrhosis, eating disorder, weight control surgical intervention, or type 2 diabetes mellitus.
• Any chronic pathology in which the intake of nutritional supplements, especially pungent components, is not recommended.
• Any condition that, in the investigator's judgment, would impair the ability to participate in the study or represent a personal risk to the participant.
• Use of medications that may affect the study results.
• Unstable body weight for 3 months prior to the start of the study (\> 4 kg loss or gain in weight).
• Active tobacco abuse or illicit drug use, or history of treatment for alcohol abuse.
• On a special diet or prescribed for other reasons (e.g., celiac disease).

Sponsors & Collaborators

• Universidad de Granada: lead
• Universidad de La Laguna, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.: collaborator

Study Sites (1)

Universidad de la Laguna

Santa Cruz de Tenerife, Spain

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD

Study Record Dates

• First Submitted: January 14, 2025
• First Posted: January 20, 2025
• Study Start: December 2, 2024
• Primary Completion: February 28, 2025
• Study Completion: February 28, 2025
• Last Updated: January 20, 2025

Record last verified: 2025-01

Locations

ES (1)